Skip to content

Addiction: all studies

Page 208 of 857: studies 2,071 to 2,080 of 8,563, newest first. Back to the addiction overview

Research

Pretreatment with the psychedelic DOI mitigates LPS-induced hippocampal inflammation and behavioral impairments in mice

BMC Neuroscience March 24, 2026 Michael Fiorillo, Javier González-Maeso

BACKGROUND: Neuroinflammation is a hallmark of numerous neuropsychiatric and neurodegenerative disorders. Psychedelics have garnered recent attention for their anti-inflammatory and neuroprotective effects. However, it remains unknown whether they can prophylactically prime immune pathways to prevent subsequent neuroinflammatory responses, and whether such effects depend on serotonin 5-HT2A...

DOI: 10.1186/s12868-026-01003-8 (opens in new tab) Hippocampal formation Neuroinflammation Neuroprotection Cytokine +13

Psilocybin: Chemical Foundations and Emerging Therapeutic Potential.

Mini-Reviews in Medicinal Chemistry March 24, 2026 Shivaputra A Patil, Holly C Hunsberger

Psilocybin, chemically known as (4-phosphoryloxy-N, N-dimethyltryptamine, 4-PODMT), is derived from the psychoactive mushroom genus, Psilocybe. Of the four active metabolites, psilocin readily enters systemic circulation. The psychoactive effects of psilocin are thought to arise through partial agonist effects at the 5-HT2A receptor. Psychedelic drugs, including psilocybin, are having a...

Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations

Expert Opinion on Pharmacotherapy March 24, 2026 Donatella Marazziti, Matteo Gambini, Riccardo Gurrieri et al.

INTRODUCTION: After decades of regulatory marginalization, psychedelic compounds have reemerged as promising therapeutic tools in psychiatry, driven by unmet clinical needs in treatment-resistant mental disorders and by growing evidence of rapid and sustained effects on mood, cognition, and behavior. AREAS COVERED: This narrative review critically examined the current clinical and regulatory...

DOI: 10.1080/14656566.2026.2654682 (opens in new tab) Clinical trial Medical prescription Medline Equity law +4

Ibogaine is associated with reorganization of high-beta brain networks in veterans with post-traumatic stress disorder

bioRxiv (Cold Spring Harbor Laboratory) March 24, 2026 Kenneth Shinozuka, Mattia Rosso, Anna Chaiken et al. 1 citation preprint

Abstract Post-traumatic stress disorder (PTSD) is a debilitating condition that affects millions of veterans. A recent observational study in 30 veterans showed that a single dose of the atypical psychedelic ibogaine can be highly effective at treating PTSD up to twelve months later. Although a prior study demonstrated that ibogaine transiently alters electroencephalography (EEG) power in...

DOI: 10.64898/2026.03.20.713241 (opens in new tab) Full text (opens in new tab) Electroencephalography Neuroimaging Biomarker Nerve net +2

Comparative genome analysis provides a foundation for defining salvinorin A biosynthesis in Salvia divinorum

Nature Communications March 23, 2026 Haixiu Li, Yuwei Sun, Wenliang Xu et al. 1 citation

The synthesis of salvinorin A by Salvia divinorum is of considerable interest for developing pain relief, anti-opioid addiction and antidepressant medications, but progress has been compromised by limited access to plant material and the complexity of the biosynthetic pathway. Initially using S. splendens, a closely related species, the first steps in the biosynthetic pathway have been...

Adolescent cannabinoid exposure delays development of prefrontal cortex perineuronal nets and inhibitory interneurons.

Neuroscience March 23, 2026 Eliza Jacobs-Brichford, Rachel M. Donka, Amy W. Lasek et al.

Maturation of inhibitory signaling during critical period development depends on neural activity driven by experience. Parvalbumin positive (PV+) interneurons, the dominant type of inhibitory interneuron in prefrontal cortex (PFC), undergo critical period development during adolescence. Their maturation is supported by perineuronal nets (PNNs), lattice-like extracellular matrix structures that...

Integrated 5-HT 2A –TrkB and G protein signaling in serotonergic psychedelic responses

bioRxiv (Cold Spring Harbor Laboratory) March 23, 2026 Marco Taddei-Tardón, Lidia Medina-Rodríguez, Jessica L Maltman et al. preprint

Abstract Serotonergic psychedelics have attracted considerable interest as promising therapeutic agents. However, the molecular mechanisms linking their acute hallucinogenic-like effects to longer-lasting neuroplastic responses remain incompletely understood, partly because of the scarcity of native neural models suitable for mechanistic studies. Here, we developed a neural stem cell-derived in...

Detecting the Earliest Recursive Regime Transition in Neural Systems

Zenodo (CERN European Organization for Nuclear Research) March 21, 2026 Charles S. Thomas preprint

Current empirical approaches to consciousness rely on measures of integration, responsiveness, and reportability, all of which track relatively late-stage phenomena. This paper introduces a minimal operational criterion for detecting an earlier event: the first sustained instance of recursive closure in neural dynamics. We argue that recursion functions as a constraint-satisfying mechanism...

Kappa-Opioid Receptor Antagonism Prolongs the Antidepressant Effects of Ketamine in Adult Mice with Depression-like Behavior Induced by Adolescent Chronic Unpredictable Stress

International Journal of Molecular Sciences March 20, 2026 Ana Zivanovic, Milos Mitic, Iva Lukic et al.

Major depressive disorder (MDD) is a highly prevalent psychiatric illness for which rapid-acting antidepressants such as ketamine provide only transient benefit. Because κ-opioid receptor (KOR) signaling contributes to stress-related dysphoria and impaired neuroplasticity, we examined whether KOR antagonism could prolong ketamine’s antidepressant-like effects in a mouse model of adolescent...

Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.

Journal of Psychoactive Drugs March 20, 2026 Marina A. M. Portes, Leandro J Bertoglio

Psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) are psychedelic compounds with therapeutic potential for depression, anxiety, and post-traumatic stress. However, their relevance to endurance athletes, who face particular psychological and physical stressors, remains underexplored. This study combines a conceptual overview...